REG - Oncimmune Hldngs PLC - PDMR Dealing
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified on 13 January 2021 that Genostics Company Limited ("Genostics"), a Person Closely Associated ("PCA") (as that term is defined in the EU Market Abuse Regulation ("MAR")) with Dr Cheung To, a Non-Executive Director of the Company, has sold ordinary shares of £0.01 each in the Company ("Ordinary Shares") as follows:
Date
No Ordinary Shares
Price (£)
11 December 2020
10,000
1.65
14 December 2020
30,000
1.675
21 December 2020
5,000
1.70
5 January 2021
50,000
1.70
5 January 2021
50,000
1.75
8 January 2021
10,000
1.85
11 January 2021
40,000
1.85
Total
195,000
Following this transaction, Genostics has a total interest in the Company of 6,215,256 Ordinary Shares, representing approximately 9.8 per cent. of the Company's issued Ordinary Share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Genostics Company Limited
2
Reason for the notification
a)
Position/status
PCA of Dr Cheung To, Non-Executive Director of the Company
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oncimmune Holdings plc
b)
LEI
213800HCYIWT6YPI1I02
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.65
10,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
11 December 2020
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.675
30,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
14 December 2020
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.70
5,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
21 December 2020
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.70
50,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
5 January 2021
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.75
50,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
5 January 2021
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.85
10,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
8 January 2021
f)
Place of the transaction
London stock exchange, AIM
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
ISIN: GB00BYQ94H38
b)
Nature of the transaction
Disposal of shares
c)
Price(s) and volume(s)
Price
Volume
£1.85
40,000
d)
Aggregated information
- Aggregated volume
Same as above
- Price
e)
Date of the transaction
11 January 2021
f)
Place of the transaction
London stock exchange, AIM
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHDKQBQCBKKFDD
Recent news on Oncimmune Holdings
See all newsREG - Oncimmune Hldgs PLC - Appointment of Nominated Adviser and Joint Broker
AnnouncementREG - Oncimmune Hldgs PLC - Holding(s) in Company
AnnouncementREG - Oncimmune Hldgs PLC - Result of General Meeting
AnnouncementREG - Oncimmune Hldgs PLC - Total Voting Rights
AnnouncementREG - Oncimmune Hldgs PLC - Holding(s) in Company
Announcement